[{"id":"f73113c5-10a0-4d17-963d-5c3a022450a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT07039877","created_at":"2025-06-28T13:39:04.007Z","updated_at":"2025-06-28T13:39:04.007Z","phase":"Phase 2","brief_title":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","source_id_and_acronym":"NCT07039877","lead_sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • bortezomib • itraconazole"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 01/02/2025","start_date":" 01/02/2025","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-06-26"},{"id":"d1947b42-42fd-4782-93fd-228a17b831b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05372367","created_at":"2022-05-12T14:59:38.525Z","updated_at":"2025-02-25T16:39:01.449Z","phase":"Phase 1","brief_title":"A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor","source_id_and_acronym":"NCT05372367","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • itraconazole • rifampicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 07/17/2024","primary_completion_date":" 07/17/2024","study_txt":" Completion: 06/13/2025","study_completion_date":" 06/13/2025","last_update_posted":"2025-02-07"},{"id":"04626dc2-433c-4bdb-b9e8-835957e85f73","acronym":"DB-1303-O-1001","url":"https://clinicaltrials.gov/study/NCT05150691","created_at":"2021-12-09T18:00:12.151Z","updated_at":"2025-02-25T13:54:07.926Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05150691 - DB-1303-O-1001","lead_sponsor":"DualityBio Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Perjeta (pertuzumab) • trastuzumab pamirtecan (BNT323) • itraconazole • ritonavir"],"overall_status":"Recruiting","enrollment":" Enrollment 766","initiation":"Initiation: 01/31/2022","start_date":" 01/31/2022","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-10-03"},{"id":"ebecafeb-a52a-4612-a3a1-e15f416b0569","acronym":"A104","url":"https://clinicaltrials.gov/study/NCT03383692","created_at":"2021-01-17T17:24:32.434Z","updated_at":"2025-02-25T14:58:35.612Z","phase":"Phase 1","brief_title":"Study of DS-8201a for Participants With Advanced Solid Malignant Tumors","source_id_and_acronym":"NCT03383692 - A104","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • itraconazole • ritonavir"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 01/12/2018","start_date":" 01/12/2018","primary_txt":" Primary completion: 09/26/2018","primary_completion_date":" 09/26/2018","study_txt":" Completion: 09/11/2023","study_completion_date":" 09/11/2023","last_update_posted":"2023-12-11"},{"id":"90a38f06-27ea-4209-9048-d2904418d6ca","acronym":"PROFILE 1001","url":"https://clinicaltrials.gov/study/NCT00585195","created_at":"2021-01-17T17:10:29.976Z","updated_at":"2024-07-02T16:35:56.286Z","phase":"Phase 1","brief_title":"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer","source_id_and_acronym":"NCT00585195 - PROFILE 1001","lead_sponsor":"Pfizer","biomarkers":" ALK • MET • CYP3A4","pipe":" | ","alterations":" ALK negative","tags":["ALK • MET • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • itraconazole • rifampicin"],"overall_status":"Completed","enrollment":" Enrollment 596","initiation":"Initiation: 04/19/2006","start_date":" 04/19/2006","primary_txt":" Primary completion: 07/30/2020","primary_completion_date":" 07/30/2020","study_txt":" Completion: 01/19/2022","study_completion_date":" 01/19/2022","last_update_posted":"2023-02-07"},{"id":"c865fa8d-eedd-4411-807c-9590facd411f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05591560","created_at":"2022-10-24T13:56:57.884Z","updated_at":"2024-07-02T16:36:01.977Z","phase":"","brief_title":"Itraconazole in Advanced Ovarian Cancer","source_id_and_acronym":"NCT05591560","lead_sponsor":"Tanta University","biomarkers":" KDR • MUC16","pipe":"","alterations":" ","tags":["KDR • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • itraconazole"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2022-10-24"},{"id":"ae1e8c24-b294-4351-8115-ef1d4ef0a78a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04018872","created_at":"2021-11-04T14:52:58.385Z","updated_at":"2024-07-02T16:36:21.182Z","phase":"Phase 2","brief_title":"Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer","source_id_and_acronym":"NCT04018872","lead_sponsor":"Dallas VA Medical Center","biomarkers":" KDR • GLI1 • GLI3 • GLI2 • SHH","pipe":" | ","alterations":" GLI3 expression","tags":["KDR • GLI1 • GLI3 • GLI2 • SHH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 06/24/2019","start_date":" 06/24/2019","primary_txt":" Primary completion: 06/24/2026","primary_completion_date":" 06/24/2026","study_txt":" Completion: 09/29/2026","study_completion_date":" 09/29/2026","last_update_posted":"2021-11-04"},{"id":"07ab0b3d-bc1a-42e9-9660-c94404b073c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00000992","created_at":"2021-01-29T06:52:48.885Z","updated_at":"2024-07-02T16:36:21.790Z","phase":"Phase 1","brief_title":"A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS","source_id_and_acronym":"NCT00000992","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 06/01/1992","study_completion_date":" 06/01/1992","last_update_posted":"2021-11-01"},{"id":"859d4daf-1a31-438b-8dbf-f8ed4a89b5e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02357836","created_at":"2021-05-03T19:53:14.312Z","updated_at":"2024-07-02T16:36:30.803Z","phase":"Phase 1","brief_title":"Neoadjuvant Itraconazole in Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02357836","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" CCND1 • PTCH1 • HIF1A • CD34 • GLI1 • CASP3 • CD31 • GLI2 • PECAM1","pipe":" | ","alterations":" MTOR mutation","tags":["CCND1 • PTCH1 • HIF1A • CD34 • GLI1 • CASP3 • CD31 • GLI2 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2021-05-03"},{"id":"bb831b25-4b1e-44f8-a3dc-5bc7d5306158","acronym":"","url":"https://clinicaltrials.gov/study/NCT02354261","created_at":"2021-01-18T11:12:06.637Z","updated_at":"2024-07-02T16:36:42.308Z","phase":"Phase 2b","brief_title":"Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)","source_id_and_acronym":"NCT02354261","lead_sponsor":"HedgePath Pharmaceuticals, Inc.","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole • Tolsura (SUBA-itraconazole)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 08/07/2015","start_date":" 08/07/2015","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-08-05"},{"id":"0bce315d-d14f-4147-a8b1-f9cc4f346fd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02608034","created_at":"2021-01-18T12:40:05.887Z","updated_at":"2024-07-02T16:36:50.102Z","phase":"Phase 1","brief_title":"A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State","source_id_and_acronym":"NCT02608034","lead_sponsor":"Genentech, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • itraconazole • rifampicin"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 05/26/2016","start_date":" 05/26/2016","primary_txt":" Primary completion: 09/10/2018","primary_completion_date":" 09/10/2018","study_txt":" Completion: 09/10/2018","study_completion_date":" 09/10/2018","last_update_posted":"2020-02-12"},{"id":"df735691-9365-486e-8de1-1ae28549d1a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04121910","created_at":"2021-01-18T20:08:44.199Z","updated_at":"2024-07-02T16:36:51.004Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole","source_id_and_acronym":"NCT04121910","lead_sponsor":"AstraZeneca","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib) • itraconazole"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 11/07/2019","start_date":" 11/07/2019","primary_txt":" Primary completion: 01/12/2020","primary_completion_date":" 01/12/2020","study_txt":" Completion: 01/12/2020","study_completion_date":" 01/12/2020","last_update_posted":"2020-01-23"},{"id":"eebab600-0270-4c73-93ad-9585470f5fa2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02735356","created_at":"2021-01-18T13:23:41.790Z","updated_at":"2024-07-02T16:37:00.682Z","phase":"Phase 1","brief_title":"Topical Itraconazole in Treating Patients With Basal Cell Cancer","source_id_and_acronym":"NCT02735356","lead_sponsor":"Jean Yuh Tang","biomarkers":" GLI1","pipe":"","alterations":" ","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole • Tolsura (SUBA-itraconazole)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 05/05/2016","start_date":" 05/05/2016","primary_txt":" Primary completion: 09/19/2017","primary_completion_date":" 09/19/2017","study_txt":" Completion: 10/10/2017","study_completion_date":" 10/10/2017","last_update_posted":"2019-04-11"},{"id":"cb37c59b-60aa-448c-a3c1-3a12036668ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT01108094","created_at":"2021-01-18T04:23:15.095Z","updated_at":"2024-07-02T16:37:05.394Z","phase":"Phase 2","brief_title":"Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas","source_id_and_acronym":"NCT01108094","lead_sponsor":"Stanford University","biomarkers":" GLI1","pipe":"","alterations":" ","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 02/01/2012","study_completion_date":" 02/01/2012","last_update_posted":"2018-11-13"},{"id":"8d0a86bc-2a9f-48de-ba1a-c4706a3277cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00045942","created_at":"2021-01-17T17:24:36.474Z","updated_at":"2024-07-02T16:37:18.951Z","phase":"Phase 2","brief_title":"PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)","source_id_and_acronym":"NCT00045942","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 D835Y • FLT3 D835","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 D835Y • FLT3 D835"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin • itraconazole"],"overall_status":"Completed","enrollment":" Enrollment 144","initiation":"Initiation: 01/30/2002","start_date":" 01/30/2002","primary_txt":" Primary completion: 03/27/2008","primary_completion_date":" 03/27/2008","study_txt":" Completion: 03/27/2008","study_completion_date":" 03/27/2008","last_update_posted":"2017-08-11"},{"id":"c40b3055-b76a-4281-b438-b731c940b17c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00045578","created_at":"2021-07-12T07:52:33.666Z","updated_at":"2024-07-02T16:37:18.942Z","phase":"Phase 1/2","brief_title":"PKC412 With or Without Itraconazole in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT00045578","lead_sponsor":"Memorial Sloan-Kettering Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 wild-type","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin • itraconazole"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 03/01/2002","start_date":" 03/01/2002","primary_txt":" Primary completion: 07/01/2004","primary_completion_date":" 07/01/2004","study_txt":"","study_completion_date":"","last_update_posted":"2017-08-11"}]